Bristol Myers Squibb, Wallingford, CT, USA OBJECTIVE: To estimate the life-time cost-effectiveness (CE) of abatacept in patients with active RA and inadequate response to MTX or anti-TNFs. METHODS: We developed a patient-level simulation model to depict progression of functional disability over time. Functional disability was expressed in terms of the Health Assessment Questionnaire Disability Index (HAQ-DI). Health-state utilities and medical-care costs were assumed to depend on HAQ DI scores. The model separately estimated CE using data from three phase III clinical trials: 1) abatacept in patients with inadequate response to MTX (AIM); 2) abatacept in patients with inadequate response to anti-TNFs (ATTAIN); and 3) abatacept or infliximab in patients with inadequate response to MTX (BMS-IM101043). Cost-effectiveness of abatacept was examined in terms of the incremental cost (2006 Canadian dollars) per quality-adjusted life-year (QALY). RESULTS: 1) AIM trial: On a lifetime basis, abatacept was estimated to yield an average of 1.4 additional QALYs per patient vs. MTX at a mean incremental cost of $54,331; the estimated CE of abatacept was $39,604 (95% CI: $38,746, $41,384) per QALY gained; 2) ATTAIN: abatacept yielded an average of 1.2 additional QALY vs. oral DMARDs alone at a mean incremental cost of $50,141; estimated CE of abatacept was $42,021 (95% CI: $40,954, $43,256) per QALY; 3) trial 043: Relative to placebo, abatacept yielded an average of 1.58 additional QALY at a mean incremental cost of $58,351; incremental CE of abatacept was $37,094 ($35,535, $38,727) per QALY; infliximab yielded an average of 1.24 additional QALY at a mean incremental cost of $53,305; incremental CE of infliximab was $43,247 ($40,845, $44,587) per QALY. Relative to infliximab, the incremental CE of abatacept was about $14,841 per QALY. CONCLUSION: Abatacept is cost-effective in patients with active RA and inadequate response to DMARD or anti-TNF therapy and also highly cost effective relative to infliximab. Bristol Myers Squibb, Wallingford, CT, USA OBJECTIVE: To estimate the life-time cost-effectiveness of abatacept relative to rituximab in patients with active rheumatoid arthritis (RA) and an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy. METHODS: We used a previously published patient level simulation model to depict progression of functional disability over time in people with active RA. Health-state utilities and medical-care costs were projected based on the Health Assessment Questionnaire Disability Index (HAQ-DI) scores. RA patients who were inadequate responders to anti-TNF therapy were assumed to receive abatacept or rituximab in combination with MTX on a lifelong basis or until therapy discontinuation due to lack of efficacy or side effects. HAQ-DI improvement at 6 months (-25% versus -22%), after adjustments for control drug response, were derived from two comparable abatacept and rituximab Phase III trials. The cost of abatacept (or rituximab) treatment was estimated at $18,480 (or $20, 500) for the first year, and at $17,160 (or $20,500) for subsequent years. Costs and health effects were discounted at 5% annually. All costs were expressed in 2007 Canadian Dollars. First order and second order uncertainty were considered. RESULTS: The reference case in the analysis is women aged 55-64 years. Relative to placebo, abatacept therapy was estimated to yield an average of 1.07 (95% confidence interval [CI] = 1.00, 1.14) additional quality adjusted life years (QALY) per patient, at a mean incremental cost of $45,875 (95% CI = $42,795, $47,773); rituximab therapy was estimated to yield an average of 0.94 (95% CI = 0.82, 1.05) additional QALY per patient, at a mean incremental cost of $51,101 (95% CI = $45,835, $57,175). Life time treatment with abatacept was estimated to be a dominant strategy compared with rituximab, primarily due to lower treatment costs and better HAQ improvement. The study findings were robust under uncertainty analyses. CONCLUSION: Abatacept therapy would be economically attractive from a Canadian payer perspective.
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